Company news: RealAge and HealthPrize; AstraZeneca and Daiichi Sankyo; Shire

Share this article:
RealAge and HealthPrize are partnering to measure the effectiveness of HealthPrize's adherence program on RealAge members taking asthma meds. The program, which will launch in June, aims to assess patient preferences for incentives – whether earning points or receiving rebates is a bigger motivator, for example. The companies said preliminary results suggest that consumers might prefer earning points over rebates. RealAge, which recently published strong results from an internal employee weight loss program, will use the findings to develop additional programs for its members on specific medications, while HealthPrize will use the data to fine-tune its adherence offering.

AstraZeneca signed a co-promotion agreement for denosumab in Japan with Daiichi Sankyo, pending approval of the drug for the treatment of bone disorders stemming from bone metastasis. Daiichi Sankyo acquired rights to the drug in Japan from Amgen in 2011 and filed for approval there in 2010.

Shire is launching a scholarship program for college students with ADHD. The Shire ADHD Scholarship Program includes a monetary award and a prepaid year of ADHD coaching services provided in partnership with Seattle nonprofit the Edge Foundation make the transition to college, vocational or technical school.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.